<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://business.gourt.com/Biotechnology-and-Pharmaceuticals/Pharmaceuticals/Tools-and-Equipment.html">
<title>Tools_and_Equipment RSS : Gourt</title>
<link>http://business.gourt.com/Biotechnology-and-Pharmaceuticals/Pharmaceuticals/Tools-and-Equipment.html</link>
<description></description>
<dc:language>en-us</dc:language>
<dc:rights>Copyright 2007, Gourt.com</dc:rights>
<dc:date>2008-09-07T22:17+29:00
</dc:date>
<dc:publisher>rtruog@gourt.com</dc:publisher>
<dc:creator>rtruog@gourt.com</dc:creator>
<dc:subject>Tools_and_Equipment RSS : Gourt</dc:subject>
<syn:updatePeriod>hourly</syn:updatePeriod>
<syn:updateFrequency>1</syn:updateFrequency>
<syn:updateBase>1901-01-01T00:00+00:00</syn:updateBase>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120527.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120356.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120522.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120546.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120555.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120558.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120447.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120339.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120342.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120353.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120363.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120393.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120335.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120331.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120333.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120336.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120345.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120234.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120206.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120165.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120104.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120124.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120127.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120129.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/120070.php" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1833880&#x26;HITNO=0&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1833880&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1589542496%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1833071&#x26;HITNO=1&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1833071&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1589008145%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1833073&#x26;HITNO=2&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1833073&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1589008300%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1832360&#x26;HITNO=3&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1832360&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1588683753%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1831372&#x26;HITNO=4&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1831372&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1588269784%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1830628&#x26;HITNO=5&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1830628&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1588009749%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1831472&#x26;HITNO=6&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1831472&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1588319859%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1828076&#x26;HITNO=7&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1828076&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1586922391%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1830209&#x26;HITNO=8&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1830209&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587852830%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1828375&#x26;HITNO=9&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1828375&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587020019%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1828604&#x26;HITNO=10&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1828604&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587126987%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1828874&#x26;HITNO=11&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1828874&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587245135%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1830285&#x26;HITNO=12&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1830285&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587888077%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1825182&#x26;HITNO=13&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1825182&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1585985735%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1827410&#x26;HITNO=14&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1827410&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1586721247%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com" />
  <rdf:li rdf:resource="http://www.economist.com/business/displaystory.cfm?story_id=12009882&#x26;fsrc=rss" />
  <rdf:li rdf:resource="http://www.economist.com/opinion/displaystory.cfm?story_id=11848309&#x26;fsrc=rss" />
  <rdf:li rdf:resource="http://www.economist.com/science/displaystory.cfm?story_id=11839246&#x26;fsrc=rss" />
  <rdf:li rdf:resource="http://www.economist.com/science/displaystory.cfm?story_id=11772685&#x26;fsrc=rss" />
  <rdf:li rdf:resource="http://www.economist.com/world/britain/displaystory.cfm?story_id=11750879&#x26;fsrc=rss" />
  <rdf:li rdf:resource="http://www.economist.com/business/displaystory.cfm?story_id=11632861&#x26;fsrc=rss" />
  <rdf:li rdf:resource="http://www.economist.com/business/displaystory.cfm?story_id=11580226&#x26;fsrc=rss" />
  <rdf:li rdf:resource="http://www.economist.com/surveys/displaystory.cfm?story_id=11565647&#x26;fsrc=rss" />
  <rdf:li rdf:resource="http://www.economist.com/people/displaystory.cfm?story_id=11529537&#x26;fsrc=rss" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://www.medicalnewstoday.com/articles/120527.php">
<title>Amgen And Wyeth Statement On The FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers</title>
<link>http://www.medicalnewstoday.com/articles/120527.php</link>
<description><![CDATA[Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers [marketed as Remicade® (infliximab), Enbrel® (etanercept), Humira® (adalimumab) and Cimzia® (certolizumab pegol)].]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120356.php">
<title>USP&#x27;s 2008 Annual Scientific Meeting To Convene Scientific Experts From Around The World</title>
<link>http://www.medicalnewstoday.com/articles/120356.php</link>
<description><![CDATA[ The U.S. Pharmacopeial (USP) Convention's 2008 Annual Scientific Meeting (ASM) will be held in Kansas City, Mo., September 24 to 26. The meeting is an opportunity to interact with the USP experts responsible for establishing internationally recognized standards for prescription and over-the-counter medicines, food ingredients and dietary supplements. The focus will be on Quality of Manufactured Medicines, Food Ingredients and Dietary Supplements.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120522.php">
<title>An Essential And Comprehensive Report On Biopharmaceuticals In The US And European Markets, By Research And Markets</title>
<link>http://www.medicalnewstoday.com/articles/120522.php</link>
<description><![CDATA[Research and Markets has announced the addition of the "Biopharmaceuticals in the US and European Markets" report to their offering.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120546.php">
<title>SARcode And Sunesis Announce Start Of Phase 1 Clinical Trial In Ocular Inflammatory Diseases</title>
<link>http://www.medicalnewstoday.com/articles/120546.php</link>
<description><![CDATA[SARcode   Corporation, a private company focused on small molecule LFA-1 inhibitors           to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq:   SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of a   small molecule LFA-1 product candidate for T-cell mediated ophthalmic              diseases.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120555.php">
<title>FDA Approves First Hepatitis B Viral Load Test</title>
<link>http://www.medicalnewstoday.com/articles/120555.php</link>
<description><![CDATA[The U.S. Food & Drug   Administration (FDA) has approved the Roche COBAS(R) TaqMan(R) HBV Test,   the first assay for quantitating Hepatitis B Virus DNA approved in the U.S.   The test uses Roche's real-time PCR technology to quantify the amount of   Hepatitis B virus DNA in a patient's blood. Doctors may use viral load   testing results to establish a baseline level of infection and during   treatment as an aid in assessing individual responses to therapy.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120558.php">
<title>Celator Pharmaceuticals Receives Orphan Drug Designation For Anticancer Agent CPX-351</title>
<link>http://www.medicalnewstoday.com/articles/120558.php</link>
<description><![CDATA[Celator Pharmaceuticals    announced that the U.S. Food & Drug Administration (FDA) has granted orphan   drug designation to CPX-351 (Cytarabine:Daunorubicin) Liposome Injection   for the treatment of Acute Myeloid Leukemia (AML).            Celator is currently preparing to conduct two randomized Phase 2                  studies with CPX-351. The first Phase 2 study, in newly diagnosed, elderly   patients with AML, is expected to start enrolling patients before the end   of 2008.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120447.php">
<title>Gilead&#x27;s Antiretroviral Patent Request Rejected By Brazil</title>
<link>http://www.medicalnewstoday.com/articles/120447.php</link>
<description><![CDATA[  A patent request from the pharmaceutical company Gilead for its antiretroviral drug tenofovir was rejected by Brazil Wednesday, Reuters reports.  After announcing the decision, a ]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120339.php">
<title>BioCryst Reports Results From BCX-4208 Phase IIa Trial In Subjects With Psoriasis</title>
<link>http://www.medicalnewstoday.com/articles/120339.php</link>
<description><![CDATA[BioCryst   Pharmaceuticals (Nasdaq: BCRX) announced results from the completed   Phase IIa trial of BCX-4208 in patients with moderate to severe plaque   psoriasis. Consistent with interim findings reported in May 2008, this   study of BCX-4208, a potent, rationally designed, orally available purine   nucleoside phosphorylase (PNP) inhibitor, met its primary objectives of   safety and tolerability.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120342.php">
<title>Agile Therapeutics Achieves Phase 2 Study Endpoints In Key Clinical Trials With New, Innovative Low-Dose Contraceptive Patch</title>
<link>http://www.medicalnewstoday.com/articles/120342.php</link>
<description><![CDATA[Agile Therapeutics, Inc.,    announced that it successfully completed two key clinical trials in      the development of the company's new, innovative low-dose, once-weekly,   contraceptive patch, which the company refers to by its internal product            code AG-200-15. The Phase 2b safety and efficacy study successfully met its   primary endpoint of ovulation suppression, cycle control and safety.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120353.php">
<title>Cystic Fibrosis Axentis Pharma Initiates Clinical Trial For Lung Infections</title>
<link>http://www.medicalnewstoday.com/articles/120353.php</link>
<description><![CDATA[Axentis Pharma AG has   initiated a clinical phase IIa trial to assess the safety and tolerability     of a new therapeutic formulation for the treatment of severe pulmonary   infection in cystic fibrosis patients. The new formulation allows an   established therapeutic agent to be delivered directly to the site of   infection. The forthcoming trial will also compare the effects of two   different doses of the new drug. Initial results are expected in summer   2009.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120363.php">
<title>QuatRx Initiates Second Phase 3 Study Of Ophena(TM) (Ospemifene Tablets) In Women With Postmenopausal Vaginal Syndrome</title>
<link>http://www.medicalnewstoday.com/articles/120363.php</link>
<description><![CDATA[QuatRx Pharmaceuticals, a   privately-held biopharmaceutical company focused on development and   commercialization of compounds to treat endocrine, metabolic and   cardiovascular disorders,  announced that it has initiated a second   Phase 3 clinical trial of Ophena(TM) (ospemifene tablets), the company's   estrogen-free oral therapy in development for the treatment of vaginal   symptoms associated with menopause.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120393.php">
<title>Bilcare GCS Expands Phase III Clinical Trial Service Capabilities</title>
<link>http://www.medicalnewstoday.com/articles/120393.php</link>
<description><![CDATA[As part of its     commitment to providing its customers with comprehensive services     that span the entire clinical supply chain, Bilcare Global Clinical     Supplies, a leading single-source provider of clinical trial supplies     and services, has enhanced its global Phase III capabilities.Â  Its     latest Phase III investments include the upgrade of its Kalish    large-scale bottling line at its U.S.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120335.php">
<title>Medarex Announces Presentations At The 33rd Congress Of The European Society For Medical Oncology</title>
<link>http://www.medicalnewstoday.com/articles/120335.php</link>
<description><![CDATA[Medarex, Inc.   (Nasdaq: MEDX) announced that nine clinical abstracts for ipilimumab,   an investigational anti-CTLA-4 antibody, in melanoma are scheduled to be   the subject of presentations at the 33rd Congress of the European Society   for Medical Oncology (ESMO) being held September 12-16, 2008 in Stockholm.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120331.php">
<title>Nanoscale Droplets With Cancer-Fighting Implications Produced By Scientists</title>
<link>http://www.medicalnewstoday.com/articles/120331.php</link>
<description><![CDATA[UCLA scientists have succeeded in making unique nanoscale droplets that are much smaller than a human cell and can potentially be used to deliver pharmaceuticals.     "What we found that was unexpected was within each oil droplet there was also a water droplet - a double emulsion," said Timothy Deming, professor and chair of the UCLA Department of Bioengineering and a member of both the California NanoSystems Institute (CNSI) at UCLA and UCLA's Jonsson Cancer Center.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120333.php">
<title>Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins</title>
<link>http://www.medicalnewstoday.com/articles/120333.php</link>
<description><![CDATA[Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) announced   that it has enrolled the first subject into its second pivotal Phase 3   clinical trial evaluating Bronchitol in cystic fibrosis sufferers.          The Phase 3 trial is being conducted in 41 hospitals across North         America, Argentina and Germany, and is the final clinical step before   Pharmaxis seeks approval to market Bronchitol for cystic fibrosis in the   United States.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120336.php">
<title>Idenix Pharmaceuticals Announces Completion Of Proof-of-Concept Study For IDX899 In Treatment-Naive HIV-Infected Patients</title>
<link>http://www.medicalnewstoday.com/articles/120336.php</link>
<description><![CDATA[Idenix   Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged   in the discovery and development of drugs for the treatment of human viral   and other infectious diseases, announced that it has completed the   proof-of-concept study evaluating IDX899, a non-nucleoside reverse   transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120345.php">
<title>Inhaled Treprostinil New Drug Application Filed By FDA</title>
<link>http://www.medicalnewstoday.com/articles/120345.php</link>
<description><![CDATA[United   Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary   Lung Rx, Inc. announced that the U.S. Food and Drug Administration   (FDA) has accepted for review the New Drug Application (NDA) for inhaled   treprostinil for the treatment of pulmonary arterial hypertension. The NDA   will be subject to a standard review period of 10 months, with a targeted   user fee deadline of April 30, 2009.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120234.php">
<title>Fast Track Drugs Reach Market Sooner, According To Tufts Center For The Study Of Drug Development</title>
<link>http://www.medicalnewstoday.com/articles/120234.php</link>
<description><![CDATA[New drugs that receive     fast track designation by the U.S. Food and Drug Administration (FDA)     experience shorter clinical and approval times compared to drugs     without the designation, according to a recently completed study of      the first decade of the fast track program conducted by the Tufts     Center for the Study of Drug Development.         Total average clinical and approval time for fast track drugs was 5%     faster than for all drugs -- 73.1 vs. 77.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120206.php">
<title>Nature Inspires New Highly Specific Drugs And Organic Products</title>
<link>http://www.medicalnewstoday.com/articles/120206.php</link>
<description><![CDATA[  The best place to seek novel compounds for pharmaceutical drugs, alternative energy sources, and a host of industrial applications, is within natural systems that have evolved over millions of years.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120165.php">
<title>Nanotechnology? Synthetic Biology? Hey, What&#x27;s That?</title>
<link>http://www.medicalnewstoday.com/articles/120165.php</link>
<description><![CDATA[  Nanotechnology and synthetic biology are two of the most exciting fields in science. They are the focus of venture capitalists, government and university laboratories, major corporations, and startup companies.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120104.php">
<title>CV Therapeutics Initiates Phase 1 Clinical Trial Of CVT-3619, A Novel Potential Treatment For Cardiometabolic Diseases</title>
<link>http://www.medicalnewstoday.com/articles/120104.php</link>
<description><![CDATA[CV Therapeutics,   Inc. (Nasdaq: CVTX) announced that the company has enrolled the first   patient in a Phase 1 trial of CVT-3619, a novel oral compound for potential   treatment of cardiometabolic diseases. The U.S. Food and Drug                  Administration recently accepted the Company's investigational new drug   application for CVT-3619, a partial A1 adenosine receptor agonist.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120124.php">
<title>Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced The Risk Of Stroke In Patients With Atrial Fibrillation</title>
<link>http://www.medicalnewstoday.com/articles/120124.php</link>
<description><![CDATA[This Analysis Showed That Multaq(R) (Dronedarone) Decreased the Risk     of Stroke by 34% in Patients With Atrial Fibrillation or Atrial Flutter   Already Adequately Treated by Antithrombotic Therapy          The results of a post-hoc analysis of the data from the ATHENA study         were presented today at the clinical trial update session of the European   Society of Cardiology congress 2008, in Munich, Germany.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120127.php">
<title>Phase III Clinical Studies Of Aclidinium Bromide Show Statistical Significance Vs. Placebo In Patients With Chronic Obstructive Pulmonary Disease</title>
<link>http://www.medicalnewstoday.com/articles/120127.php</link>
<description><![CDATA[Forest Laboratories, Inc.   (NYSE: FRX) and Laboratorios Almirall, S.A. announced results from   two global Phase III studies of aclidinium bromide, a novel long-acting   inhaled anticholinergic for the treatment of patients with chronic                   obstructive pulmonary disease (COPD).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120129.php">
<title>Prasugrel Significantly Reduced New Or Recurrent Heart Attacks In Both Acute And Longer-Term Settings Following PCI, Compared With Clopidogrel</title>
<link>http://www.medicalnewstoday.com/articles/120129.php</link>
<description><![CDATA[A sub-analysis of   the TRITON-TIMI 38 clinical trial showed that treatment with prasugrel   compared with clopidogrel significantly reduced the risk of new or                   recurrent heart attacks (7.4 percent vs. 9.7 percent, p]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/120070.php">
<title>Whistle-Blower Lawsuits Helped Recover At Least $9.3B From Health Care Providers Accused Of Defrauding States, Federal Government, Analysis Finds</title>
<link>http://www.medicalnewstoday.com/articles/120070.php</link>
<description><![CDATA[    Whistle-blowers have helped the Department of Justice recover at least $9.3 billion from health care providers and pharmaceutical companies that allegedly defrauded states and the federal government, according to a report published recently in the Annals of Internal Medicine, the ]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1833880&#x26;HITNO=0&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1833880&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1589542496%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1833880&#x26;HITNO=0&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1833880&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1589542496%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[SmartBrief:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1833071&#x26;HITNO=1&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1833071&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1589008145%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>Cougar Biotechnology to Present at Morgan Stanley Global Healthcare Conference</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1833071&#x26;HITNO=1&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1833071&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1589008145%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[Pharma Live:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1833073&#x26;HITNO=2&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1833073&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1589008300%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1833073&#x26;HITNO=2&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1833073&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1589008300%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[Pharma Live:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1832360&#x26;HITNO=3&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1832360&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1588683753%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1832360&#x26;HITNO=3&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1832360&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1588683753%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[Drugs.com:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1831372&#x26;HITNO=4&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1831372&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1588269784%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>High Growth Forecasted for the In Vitro Diagnostics Market Report and Analysis 2008-2023</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1831372&#x26;HITNO=4&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1831372&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1588269784%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[Interest!ALERT:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1830628&#x26;HITNO=5&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1830628&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1588009749%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>RNCOS Releases a New Report- Asia Pacific Biotechnology Market (2008-2012)</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1830628&#x26;HITNO=5&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1830628&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1588009749%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[24-7PressRelease.com:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1831472&#x26;HITNO=6&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1831472&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1588319859%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>Quinnova Pharmaceuticals, Inc</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1831472&#x26;HITNO=6&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1831472&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1588319859%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[BioSpace:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1828076&#x26;HITNO=7&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1828076&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1586922391%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>Cyprus and Ireland Add Wyeth&#x27;s 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation S</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1828076&#x26;HITNO=7&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1828076&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1586922391%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[Pharma Live:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1830209&#x26;HITNO=8&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1830209&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587852830%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>Gryphon Investors Recapitalizes Synteract and Vince &#x26; Associates</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1830209&#x26;HITNO=8&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1830209&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587852830%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[Pharma Live:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1828375&#x26;HITNO=9&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1828375&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587020019%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1828375&#x26;HITNO=9&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1828375&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587020019%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[SmartBrief:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1828604&#x26;HITNO=10&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1828604&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587126987%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>SAFC Pharma Commits to Major Expansion of High Potency API Production at Madison Site</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1828604&#x26;HITNO=10&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1828604&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587126987%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[Pharma Live:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1828874&#x26;HITNO=11&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1828874&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587245135%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>Cyprus and Ireland Add Wyeth&#x27;s 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation S</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1828874&#x26;HITNO=11&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1828874&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587245135%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[KRON4:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1830285&#x26;HITNO=12&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1830285&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587888077%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>Abbott to Present at Bank of America 38th Annual Investment Conference</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1830285&#x26;HITNO=12&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1830285&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1587888077%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[Calibre Macro World:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1825182&#x26;HITNO=13&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1825182&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1585985735%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>Applikon Biotechnology B.V. Announces Management Buy-Out</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1825182&#x26;HITNO=13&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1825182&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1585985735%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[Bioresearch Online:]]></description>
</item>

<item rdf:about="http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1827410&#x26;HITNO=14&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1827410&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1586721247%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com">
<title>High Growth Forecasted for the In Vitro Diagnostics Market Report and Analysis 2008-2023</title>
<link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&#x26;ID=1827410&#x26;HITNO=14&#x26;MSIZE=1000&#x26;LANGUAGE=en&#x26;FILE=doc.NEWSFEED&#x26;SAVEQUERY00=biotechnology%20pharmaceutical&#x26;SAVEPROP00=L%3den&#x26;SAVEDB=news&#x26;SAVEORGANISE_CODED=R:date&#x26;R=1827410&#x26;THISHREF=http://c.moreover.com/click/here.pl%3fz1586721247%26amp%3bz%3d950242273&#x26;THEHOST=site+d.moreover.com</link>
<description><![CDATA[TMC Net:]]></description>
</item>

<item rdf:about="http://www.economist.com/business/displaystory.cfm?story_id=12009882&#x26;fsrc=rss">
<title>Pharmaceuticals: Convergence or conflict? </title>
<link>http://www.economist.com/business/displaystory.cfm?story_id=12009882&#x26;fsrc=rss</link>
<description><![CDATA[Drug giants&#8217; recent attempts to buy big biotech firms have provoked a backlashDALLIANCES between conventional pharmaceutical companies and biotechnology firms are nothing new. Big Pharma, eager to refill its emptying drug pipelines, has in recent years looked hopefully to biotech&#8217;s upstarts. The drugs giants have pursued all sorts of tie-ups, from alliances to licensing deals to outright purchases of a few smallish companies. But mindful of the sharp cultural differences between the two sorts of firms, they have generally avoided big acquisitions.Until now, that is. In recent weeks Roche, a Swiss pharmaceuticals giant, has made a surprise $44 billion bid for the 44% of Genentech, the world&#8217;s biggest biotech firm by stockmarket value, that it does not already own; and Bristol-Myers Squibb (BMS), an American drugs company, has offered $4.5 billion for the 83% of ImClone, an American biotech firm, that it does not already control. These attempts came on the heels of earlier deals in which AstraZeneca, a British drugs giant, bought MedImmune for $15.6 billion, and Takeda of Japan paid $8.8 billion for Millennium. ...]]></description>
</item>

<item rdf:about="http://www.economist.com/opinion/displaystory.cfm?story_id=11848309&#x26;fsrc=rss">
<title>Gene doping: Fairly safe </title>
<link>http://www.economist.com/opinion/displaystory.cfm?story_id=11848309&#x26;fsrc=rss</link>
<description><![CDATA[What athletes may or may not do ought to be decided on grounds of safety, not fairnessANOTHER Olympics, another doping debate. And this time it is a fervent one, as recent advances in medical science have had the side-effect of providing athletes with new ways of enhancing performance, and thus of putting an even greater strain on people&#8217;s ethical sensibilities. This is especially true of gene therapy. Replacing defective genes holds out great promise for people suffering from diseases such as muscular dystrophy and cancer. But administered to sprightly sportsmen, the treatment may allow them to heave greater weights, swim faster and jump farther (see article). And that would be cheating, wouldn&#8217;t it? ...]]></description>
</item>

<item rdf:about="http://www.economist.com/science/displaystory.cfm?story_id=11839246&#x26;fsrc=rss">
<title>Gene doping: Genetically Modified Olympians? </title>
<link>http://www.economist.com/science/displaystory.cfm?story_id=11839246&#x26;fsrc=rss</link>
<description><![CDATA[On the eve of the Beijing Olympics, we examine the prospect of athletes using gene therapy to enhance their performance&#8212;and of catching them if they tryFOR as long as people have vied for sporting glory, they have also sought shortcuts to the champion&#8217;s rostrum. Often, those shortcuts have relied on the assistance of doctors. After all, most doping involves little more than applying existing therapies to healthy bodies. These days, however, the competition is so intense that existing therapies are not enough. Now, athletes in search of the physiological enhancement they need to take them a stride ahead of their opponents are scanning medicine&#8217;s future, as well as its present. In particular, they are interested in a field known as gene therapy. Gene therapy works by inserting extra copies of particular genes into the body. These extra copies, known as &#8220;transgenes&#8221;, may cover for a broken gene or regulate gene activity. Though gene therapy has yet to yield a reliable medical treatment, more than 1,300 clinical trials are now under way. As that number suggests, the field is reckoned to be full of promise. ...]]></description>
</item>

<item rdf:about="http://www.economist.com/science/displaystory.cfm?story_id=11772685&#x26;fsrc=rss">
<title>Tech.view: It&#x26;#8217;s in your genes&#x26;#8212;maybe </title>
<link>http://www.economist.com/science/displaystory.cfm?story_id=11772685&#x26;fsrc=rss</link>
<description><![CDATA[Peering into your medical future is riskyIT HAS already delivered ever cheaper and more powerful computers. Now Moore&#8217;s Law&#8212;the prediction four decades ago by Gordon Moore, one of the founders of Intel, that computer chips would roughly double in performance every 18 months or so&#8212;is promising to turbo-charge our health care as well. The &#8220;genome chip&#8221;&#8212;a matchbox-sized micro-array, fabricated on a slither of silicon or quartz, that can detect 1m or more specific genetic variations in an individual&#8217;s DNA at a time&#8212;is following an even steeper price-performance curve than Mr Moore ever imagined. ...]]></description>
</item>

<item rdf:about="http://www.economist.com/world/britain/displaystory.cfm?story_id=11750879&#x26;fsrc=rss">
<title>Assisted reproduction: No IVF please, we&#x26;#8217;re British </title>
<link>http://www.economist.com/world/britain/displaystory.cfm?story_id=11750879&#x26;fsrc=rss</link>
<description><![CDATA[ Test-tube babies are rare in the country where the first was born&#8220;BABY of the century&#8221; ran the front-page headline of the Daily Express on July 11th, 1978. The paper promised the story of Lesley Brown, who was barricaded inside Oldham and District General Hospital, near Manchester, waiting to give birth. The world&#8217;s press was camped outside; the front doors locked and staff forced to sneak in and out via a side entrance. Patrick Steptoe and Robert Edwards, the obstetrician and physiologist who had, nine months before, taken an egg from one of Mrs Brown&#8217;s ovaries under anaesthetic and fertilised it in vitro with her husband&#8217;s sperm, were in hiding. It had been, said Time magazine after Mrs Brown was delivered of a daughter on July 25th, &#8220;the most awaited birth in perhaps 2,000 years&#8221;.Thirty years after Louise Brown was born, &#8220;test-tube babies&#8221; are commonplace. Around the world 3.5m have been born and at least 200,000 more join them each year. Yet infertile people in the country where it all began are among the least likely in the rich world to receive what is now a standard treatment for their condition. Just under 700 attempts at in vitro fertilisation (IVF) are carried out per million Britons each year, one of the lowest rates in Europe. The 11,262 IVF babies born in Britain in 2005, the latest year for which figures are available, were just 1.6% of all births, compared with rates of 3-3.5% in the Nordic countries (see chart). ...]]></description>
</item>

<item rdf:about="http://www.economist.com/business/displaystory.cfm?story_id=11632861&#x26;fsrc=rss">
<title>Industrial biotechnology: Better living through chemurgy </title>
<link>http://www.economist.com/business/displaystory.cfm?story_id=11632861&#x26;fsrc=rss</link>
<description><![CDATA[ Efforts to replace oil-based chemicals with renewable alternatives are taking offFORTY years ago Dustin Hoffman&#8217;s character in &#8220;The Graduate&#8221; was given a famous piece of career advice: &#8220;Just one word&#8230;plastics.&#8221; It was appropriate at the time, given that the 1960s were a golden age of petrochemical innovation. Oil was cheap and seemed limitless. Since then, scientists have kept on coming up with wondrous new products made from petroleum that helped to ensure, in the words of one corporate slogan, better living through chemistry. Even so, someone offering advice to today&#8217;s promising graduates might invoke a different, uglier word: chemurgy. This term, coined in the 1930s, refers to a branch of applied chemistry that turns agricultural feedstocks into industrial and consumer products. It had several successes early in the 20th century. Cellulose was used to make everything from paint brushes to the film on which motion pictures were captured. George Washington Carver, an American scientist, developed hundreds of ways to convert peanuts, sweet potatoes and other crops into glue, soaps, paints, dyes and other industrial products. In the 1930s Henry Ford started using parts made from agricultural materials, and even built an all-soy car. But the outbreak of the second world war and the shift to wartime production halted his experiment. After the war, low oil prices and breakthroughs in petrochemical technologies ensured the dominance of petroleum-based plastics and chemicals.  ...]]></description>
</item>

<item rdf:about="http://www.economist.com/business/displaystory.cfm?story_id=11580226&#x26;fsrc=rss">
<title> Biotechnology: Getting personal</title>
<link>http://www.economist.com/business/displaystory.cfm?story_id=11580226&#x26;fsrc=rss</link>
<description><![CDATA[A genomics merger highlights the potential for personalised medicineFANS of genomics have long argued that decoding genomes one person at a time would revolutionise health care by leading to &#8220;personalised&#8221; medicine, in which doctors match the treatment to the individual. As the cost of gene sequencing has fallen, firms have rushed to offer genetic tests directly to consumers, often raising grand expectations. There now seems to be a backlash. Doctors have groused about being bypassed. Punters have grown wary as they realise that most such tests do not provide conclusive evidence of the risk of disease. This month officials in California even sent warning letters to marketers of such genetic tests, as part of an effort to rein in this unruly new industry.So will the genomics revolution now grind to a halt? No. But it may well unfold in more conventional ways than enthusiasts of &#8220;disruptive innovation&#8221; had hoped. To see why, consider this month's acquisition by Invitrogen, a biotechnology firm based near San Diego, of Applied Biosciences (AB), a bigger firm also based in California, in a deal valued at over $6 billion. The combination will be a force in the market for gene-sequencing equipment (which AB makes) and the related products and services (Invitrogen's bread and butter) that complement the hardware.  ...]]></description>
</item>

<item rdf:about="http://www.economist.com/surveys/displaystory.cfm?story_id=11565647&#x26;fsrc=rss">
<title>Bespoke biofuels</title>
<link>http://www.economist.com/surveys/displaystory.cfm?story_id=11565647&#x26;fsrc=rss</link>
<description><![CDATA[The biofuels of the future will be tailor-madeBURIED in the news a few weeks ago was an announcement by a small Californian firm called Amyris. It was, perhaps, a parable for the future of biotechnology. Amyris is famous in the world of tropical medicine for applying the latest biotechnological tools to the manufacture of artemisinin, an antimalarial drug that is normally extracted from a Chinese vine. The vines cannot produce enough of the stuff, though, so Amyris&#8217;s researchers have taken a few genes here and there, tweaked them and stitched them together into a biochemical pathway enabling bacteria to make a chemical precursor that can easily be converted into the drug. But that is not what the announcement was about. Instead, it was that Amyris was going into partnership with Crystalsev, a Brazilian firm, to make car fuel out of cane sugar. Not ethanol (though Brazil already has a thriving market for ethanol-powered cars), but a hydrocarbon that has the characteristics of diesel fuel. Technically, it is not ordinary diesel, either: in chemist-speak, it is an isoprenoid rather than a mixture of alkanes and aromatics. But the driver will not notice the difference. ...]]></description>
</item>

<item rdf:about="http://www.economist.com/people/displaystory.cfm?story_id=11529537&#x26;fsrc=rss">
<title> Face value: From across the divide</title>
<link>http://www.economist.com/people/displaystory.cfm?story_id=11529537&#x26;fsrc=rss</link>
<description><![CDATA[Europe's biotech firms need to think big if they are to prosper, says Lisa Drakeman of GenmabIS EUROPE'S biotechnology industry finally ready for the big time? For decades the continent's scientific elite watched as boffins in America fled academia to start biotech firms. European governments poured billions of euros into &#8220;technology corridors&#8221;, &#8220;poles de competitivite&#8221;, and other top-down schemes to create biotech clusters. But most of the venture capital still went to American firms, and Europe failed to produce a rival to America's Amgen or Genentech. Defenders of Europe's efforts to promote innovation in biotechnology noisily object to this view. To show that Europe's efforts may at last be paying off, they point to a recent uptick in investment&#8212;and to Genmab, a Danish firm led by Lisa Drakeman. And what does she think? Hers is an unusual perspective, for as well as being boss of one of Europe's biggest biotech firms, Ms Drakeman is American.Ms Drakeman calls herself an &#8220;accidental CEO&#8221; because she came to her job via an unusual route. After a doctorate at Princeton in the history of religion, she went to work at Medarex, an American biotech firm that her husband was just getting off the ground in the 1980s. It went public in 1991, and Ms Drakeman moved into business-development in 1993. She spotted an opening, based on the work of a Dutch scientist who was advising Medarex, and proposed to set up a company. But American venture capitalists were unwilling to back the idea. Instead a Danish investor, BankInvest, came forward&#8212;and proposed that Ms Drakeman herself should lead it. So Genmab was set up in Copenhagen, though its research facilities are in the Netherlands. ...]]></description>
</item>

</rdf:RDF>